
Include peer‑reviewed or news‑worthy articles that report on new therapeutic discoveries, clinical trial outcomes, gene‑editing or immunotherapy advances, AI applications in drug discovery, FDA/EMA approvals, regulatory guidance, biotech financing, M&A, startup launches, market forecasts, and conference summaries directly relevant to pharma/biotech. Exclude pieces that focus solely on medical devices, unrelated AI/health‑payment platforms, generic promotional or sponsored content without clear pharma/biotech relevance, and routine operational updates that do not contain substantive scientific, regulatory, or commercial insight.
Peer‑reviewed pharma and biotech breakthroughs, trials, AI, regulatory updates, financing and M&A, market trends
Explore the latest content curated by BioPharma Pulse
AI promises assay efficiency, but CSV-grade validation is missing—what minimal metrics will regulators accept? Watch AI-bioanalysis.
Fatal liver event spotlights CRISPR safety risk—when will sponsors embed real-time biomarker tracking and lot-traceability? Watch regulatory-risk.
Amylin analogs could diversify obesity pipelines—track muscle‑sparing claims and CMC scale as data mature.
Nausea curbs GLP‑1 upside—investors should flag adherence gaps and potential anti‑emetic combos.
Early‑line SC daratumumab reshapes SMM care—watch hyaluronidase supply and fill‑finish capacity as CMC risk climbs.
FDA vaccine‑center turmoil spikes regulatory risk—UniQure’s AMT-130 setback underscores need for robust RWE and timeline buffers. #watchRegulatory‑risk
Subscribe for curated content or create your own curator